<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We sought to determine whether <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> alter NEFA-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and, if so, the mechanism whereby this is effected </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Euglycaemic-hyperinsulinaemic clamps (<z:chebi fb="105" ids="17234">glucose</z:chebi> approximately 5.3 mmol/l, insulin approximately 200 pmol/l) were performed in the presence of Intralipid-<z:chebi fb="5" ids="28304">heparin</z:chebi> (IL/H) or <z:chebi fb="3" ids="17754">glycerol</z:chebi> before and after 4 months of treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (n = 11) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (n = 9) in diabetic participants </plain></SENT>
<SENT sid="2" pm="."><plain>Hormone secretion was inhibited with somatostatin in <z:hpo ids='HP_0000001'>all</z:hpo> participants </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> increased insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> disappearance (p &lt; 0.01) and increased insulin-induced suppression of <z:chebi fb="105" ids="17234">glucose</z:chebi> production (p &lt; 0.01), gluconeogenesis (p &lt; 0.05) and glycogenolysis (p &lt; 0.05) during IL/H </plain></SENT>
<SENT sid="4" pm="."><plain>However, <z:chebi fb="105" ids="17234">glucose</z:chebi> disappearance remained lower (p &lt; 0.05) whereas <z:chebi fb="105" ids="17234">glucose</z:chebi> production (p &lt; 0.01), gluconeogenesis (p &lt; 0.05) and glycogenolysis (p &lt; 0.05) were higher on the IL/H study day than on the <z:chebi fb="3" ids="17754">glycerol</z:chebi> study day, indicating persistence of NEFA-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> increased (p &lt; 0.001) <z:chebi fb="105" ids="17234">glucose</z:chebi> disappearance during IL/H to rates present during <z:chebi fb="3" ids="17754">glycerol</z:chebi> treatment, indicating protection against NEFA-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in extrahepatic tissues </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:chebi fb="105" ids="17234">glucose</z:chebi> production and gluconeogenesis (but not glycogenolysis) were higher (p &lt; 0.01) during IL/H than during <z:chebi fb="3" ids="17754">glycerol</z:chebi> treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi>, indicating persistence of NEFA-induced hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: We conclude that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> improves both the hepatic and the extrahepatic action of insulin but does not prevent NEFA-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, whereas <z:chebi fb="0" ids="6801">metformin</z:chebi> prevents NEFA-induced extrahepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, it does not protect against NEFA-induced hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>